Tramadol Hydrochloride
Product Images NDC 70934-531

4 FDA label images from Denton Pharma, Inc. Dba Northwind Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Tramadol Hydrochloride (NDC 70934-531). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (70934 531 30 Master Bottle Label Approval Rev A 01 20)

Label (70934 531 30 Master Bottle Label Approval Rev A 01 20)
Label for Tramadol Hydrochloride Tablets USP 50 mg, containing 30 tablets, manufactured by Denton Pharma, Inc. DBA Northwind Pharmaceuticals. The label includes NDC 70934-531-30, storage instructions, dosage caution, and a peel-here section revealing additional tablets' NDC and manufacturing information.*
FDA Label Image

Structure (Tramadol 1)

Structure (Tramadol 1)
Chemical structure of tramadol hydrochloride showing its molecular framework including a benzene ring with methoxy and hydroxyl groups, a cyclohexane ring, and an amine side chain associated with hydrochloride.*
FDA Label Image

Figure 1 (Tramadol 2)

Figure 1 (Tramadol 2)
A pharmacokinetic concentration versus time graph showing plasma concentrations (ng/mL) of Tramadol and its metabolite M1 after single and multiple doses over a 48-hour period. The graph compares concentrations for multiple dose Tramadol, single dose Tramadol, multiple dose M1, and single dose M1.*
FDA Label Image

Figure 2 (Tramadol 3)

Figure 2 (Tramadol 3)
A line plot titled 'Protocol CAPSS-047 Time to Discontinuation Due to Nausea/Vomiting' that depicts percent discontinuing on the vertical axis against days in double-blind on the horizontal axis for a 10-day dosage regimen reaching 200 mg/day. The graph shows a generally increasing trend of discontinuation over the 25-day period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.